Dilpacimab Biosimilar – Anti-DLL4, VEGFA mAb – Research Grade

Description of Dilpacimab Biosimilar - Anti-DLL4, VEGFA mAb - Research Grade

Dilpacimab Biosimilar – Anti-DLL4, VEGFA mAb – Research Grade: A Promising Therapeutic Antibody Dilpacimab Biosimilar is a monoclonal antibody (mAb) targeting two important therapeutic targets – Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGFA). This research-grade antibody has shown great potential in treating various diseases, making it a promising candidate for future therapeutic use.

Structure of Dilpacimab Biosimilar

Dilpacimab Biosimilar is a recombinant humanized IgG1 mAb, with a molecular weight of approximately 150 kDa. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The heavy chains consist of constant and variable regions, while the light chains have only variable regions. The variable regions of the antibody are responsible for binding to their targets – DLL4 and VEGFA.

The structure of Dilpacimab Biosimilar is designed to mimic the structure of natural antibodies, making it highly specific and effective in targeting its therapeutic targets. This specificity is crucial in minimizing potential side effects and maximizing the therapeutic benefits of the antibody.

Activity of Dilpacimab Biosimilar

The main activity of Dilpacimab Biosimilar is to block the signaling pathways of DLL4 and VEGFA. DLL4 is a ligand that plays a critical role in the Notch signaling pathway, which is involved in cell proliferation, differentiation, and survival. By blocking DLL4, Dilpacimab Biosimilar inhibits the activation of Notch signaling, leading to the suppression of tumor growth and angiogenesis.

VEGFA, on the other hand, is a key regulator of blood vessel formation. It promotes the growth of new blood vessels, which is essential for tumor growth and metastasis. Dilpacimab Biosimilar binds to VEGFA and prevents it from binding to its receptors, thereby inhibiting the formation of new blood vessels and reducing the blood supply to tumors.

In addition to its anti-tumor activity, Dilpacimab Biosimilar has also shown potential in treating other diseases, such as age-related macular degeneration and diabetic retinopathy. These conditions are characterized by abnormal blood vessel growth in the eye, and Dilpacimab Biosimilar’s ability to block VEGFA makes it a promising therapeutic option.

Application of Dilpacimab Biosimilar

Dilpacimab Biosimilar is currently being studied in preclinical and clinical trials for its potential use in various diseases. Its anti-tumor activity has shown promising results in several types of cancer, including colorectal, lung, and breast cancer. It has also shown potential in combination with other therapies, such as chemotherapy and radiation, to enhance their effectiveness.

In addition to its use as a therapeutic agent, Dilpacimab Biosimilar is also being studied for its diagnostic potential. Due to its high specificity for DLL4 and VEGFA, it can be used as a biomarker for the detection and monitoring of certain diseases.

Conclusion

Dilpacimab Biosimilar – Anti-DLL4, VEGFA mAb – Research Grade is a promising therapeutic antibody with a unique dual-targeting mechanism. Its specificity and activity against DLL4 and VEGFA make it a potential treatment option for various diseases, particularly cancer. With ongoing research and clinical trials, Dilpacimab Biosimilar has the potential to make a significant impact in the field of medicine and improve the lives of patients worldwide.

Dilpacimab Biosimilar - Anti-DLL4, VEGFA mAb binds to VEGFA / VEGF165, C-His, recombinant protein in indirect ELISA Assay

Immobilized VEGFA / VEGF165, C-His, recombinant protein (cat. No.PX-P5977) at 0.5µg/mL (100µL/well) can bind to Dilpacimab Biosimilar - Anti-DLL4, VEGFA mAb (cat. No.PX-TA1525) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450